

# Cobalt-Catalyzed Decarboxylative 2-Benzoylation of Oxazoles and Thiazoles with $\alpha$ -Oxocarboxylic Acids


Ke Yang,<sup>†,§</sup> Xinyong Chen,<sup>†,§</sup> Yuqi Wang,<sup>†</sup> Wanqing Li,<sup>†</sup> Adnan A. Kadi,<sup>‡</sup> Hoong-Kun Fun,<sup>‡</sup> Hao Sun,<sup>\*,†</sup> Yan Zhang,<sup>†,‡</sup> Guigen Li,<sup>\*,†</sup> and Hongjian Lu<sup>\*,†</sup>

<sup>†</sup>Institute of Chemistry & BioMedical Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, China

<sup>‡</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

## Supporting Information

**ABSTRACT:** Cobalt-catalyzed decarboxylative cross-coupling of oxazoles and thiazoles with  $\alpha$ -oxocarboxylic acids was developed through an  $sp^2$  C–H bond functionalization process. This work represents the first example of cobalt-catalyzed decarboxylative C–H bond functionalization and provides an efficient means of building some important bioactive heteroaryl ketone derivatives.



The transition-metal-catalyzed C–H functionalization process allows simplification and abbreviation of synthetic procedures and is one of the most powerful and facile methods with which to construct complex molecules in synthetic organic and medicinal chemistry.<sup>1</sup> Recently, cobalt-catalyzed C–H functionalization has met with success due to its economy, low toxicity, and interesting reaction modes.<sup>2,3</sup> Many C–C<sup>4</sup> and C–heteroatom<sup>5</sup> bond-forming reactions have been achieved by this method since the first example of a cobalt-catalyzed chelation-assisted C–H functionalization process was reported by Murahashi.<sup>4x</sup> Because of their value in synthetic chemistry, C–C bond-forming reactions have attracted significant attention, and various reagents including *N*-tosylhydrazones, *N*-cyanosuccinimide, alkyl and aryl halides, sulfamates, aziridines, alkenes, and alkynes have been utilized as coupling partners.<sup>2,4</sup> In the meanwhile, transition-metal-catalyzed decarboxylative cross-coupling reactions of (hetero)arenes with carboxylic acids through  $sp^2$  C–H bond functionalization have also received attention because of the low cost, stability, and general availability of carboxylic acids, one of the coupling partners.<sup>6</sup> Since 2008,<sup>7m</sup> Pd complexes have been recognized as the most efficient catalysts in decarboxylative C–H functionalization for the construction of versatile C–C bonds.<sup>7–9</sup> Other transition-metal complexes, including Rh, Ag, Cu, and Ni complexes, have very recently emerged as efficient catalysts,<sup>10</sup> but no decarboxylative C–H functionalization processes through cobalt catalysis have been reported to date.

2-Substituted oxazoles and thiazoles are present in many medicinally active compounds with a diverse array of biological activities, medicines, and functional materials.<sup>11</sup> Previous methods for the direct synthesis of 2-substituted oxazoles and thiazoles rely primarily on transition-metal-catalyzed direct C–2 functionalizations of oxazoles and thiazoles.<sup>4r,7b,10a,b,12</sup> Although many transition-metal-catalyzed direct C–2 functionalizations have been reported, the success of direct C–2


acylation is still rare.<sup>10a,12f,n</sup> To continue our efforts on cobalt-catalyzed C–H functionalization<sup>5e,j</sup> and metal-catalyzed decarboxylative acylation of oxazoles,<sup>10a</sup> we disclose the cobalt-catalyzed 2-benzoylation of oxazoles and thiazoles with  $\alpha$ -oxocarboxylic acids through an  $sp^2$  C–H bond functionalization reaction. This process represents the first example of decarboxylative cross-couplings via an  $sp^2$  C–H functionalization process with cobalt catalysis.

Initially, we examined the decarboxylative cross-coupling of benzoxazole (**1a**) and 2-oxo-2-phenylacetic acid (**2a**) with CoCl<sub>2</sub> in the presence of Ag<sub>2</sub>CO<sub>3</sub> at 170 °C. After extensive screening of solvents, 3-fluorobenzotrifluoride (3-F-C<sub>6</sub>H<sub>4</sub>CF<sub>3</sub>) was found to be optimal, and with this solvent, the desired product benzo[*d*]oxazol-2-yl(phenyl)-methanone (**3a**) was obtained in 72% yield (Table 1, entries 1–6). Subsequently, various cobalt catalysts were examined, and we found that the reaction could be effectively catalyzed by a variety of cobalt(II) complexes, including Co(OAc)<sub>2</sub>·4H<sub>2</sub>O, CoSO<sub>4</sub>·7H<sub>2</sub>O, Co(acac)<sub>2</sub>, CoCO<sub>3</sub>·H<sub>2</sub>O, and Co(ClO<sub>4</sub>)<sub>2</sub>·6H<sub>2</sub>O (entries 7–12). Cobalt(III) species, such as Co(acac)<sub>3</sub> and Co(bpy)<sub>3</sub>(ClO<sub>4</sub>)<sub>3</sub>, were also found to catalyze the reaction, albeit in low yield (entries 13 and 14). These investigations identified Co(ClO<sub>4</sub>)<sub>2</sub>·6H<sub>2</sub>O as the most efficient catalyst, which provided the desired product **3a** in 92% isolated yield. Additionally, we found that replacement of Ag<sub>2</sub>CO<sub>3</sub> with other oxidants, such as K<sub>2</sub>S<sub>2</sub>O<sub>8</sub>, AgOAc, or Ag<sub>2</sub>O, produced a low yield of the desired product **3a** (entries 15–17). Finally, in the absence of the Co catalyst, only a trace amount of product **3a** was formed (entry 18).

With the optimum conditions defined, we explored the scope of the oxazole substrates. The current catalytic system proceeds smoothly to provide 2-acylated substituted oxazoles in good yield (Table 2). Both electron-donating (Me) and electron-

Received: June 26, 2015

Published: October 9, 2015


Table 1. Optimization of Reaction Conditions<sup>a</sup>

<sup>a</sup>Reaction conditions: **1a** (0.2 mmol), **2a** (0.6 mmol), Co source (10 mol %), additives (0.6 mmol), 2 mL of solvent, 170 °C, 24 h. <sup>b</sup>Yields are based on **1a**, determined by crude <sup>1</sup>H NMR using dibromomethane as the internal standard. <sup>c</sup>35% of **1a** isolated. <sup>d</sup>Isolated yield.


withdrawing groups (Cl and Br) on the phenyl ring of benzoxazole are tolerated (**3b–g**), and this provides more options for further potential transformations. Furthermore, both mono- and disubstituted oxazoles were effective coupling partners, and the desired products were isolated in good yield (**3h–k**). Next, the substrate scope study of  $\alpha$ -oxocarboxylic acids was also examined. As shown in Table 3, *para*- or *meta*-substituted phenylglyoxylic acids, with either an electron-donating or an electron-withdrawing group on the phenyl ring, were good substrates in the coupling reaction (**3l–3t**). In addition, we found that there were no desired products formed when *ortho*-chloro-substituted phenylglyoxylic acid, 4-methyl-2-oxopentanoic acid, or 2-cyclopropyl-2-oxoacetic acid were used as the coupling reagents.

We also explored the substrate scope of thiazoles and  $\alpha$ -oxocarboxylic acids in the presence of cobalt catalysts. In the reaction of benzothiazole **4a** with 2-oxo-2-phenylacetic acid (**2a**) under standard conditions, 31% yield of the desired product **5a** was formed and 37% of **4a** was recovered. Obvious decomposition was observed, probably due to the oxidative property of Co(ClO<sub>4</sub>)<sub>2</sub>·6H<sub>2</sub>O. Rescreening of the cobalt catalysts identified Co(OAc)<sub>2</sub>·4H<sub>2</sub>O as the optimal catalyst in the presence of Ag<sub>2</sub>CO<sub>3</sub> and 3-fluorobenzotrifluoride at 170 °C (Table 4). Various  $\alpha$ -oxocarboxylic acids **2** and thiazoles **4** were well tolerated under these reaction conditions, providing the desired products in moderate to good yield (**5a–5i**).


To gain insight into the reaction mechanism, some preliminary experiments were performed as depicted in

Table 2. Scope of Oxazole Derivatives<sup>a</sup>

<sup>a</sup>Reaction conditions: **1** (0.2 mmol), **2a** (0.6 mmol), Co(ClO<sub>4</sub>)<sub>2</sub>·6H<sub>2</sub>O (10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (3.0 equiv), 3-fluorobenzotrifluoride (2 mL), 170 °C, 24 h. Isolated yields. <sup>b</sup>36 h.

Table 3. Scope of  $\alpha$ -Oxocarboxylic Acids<sup>a</sup>

<sup>a</sup>Reaction conditions: 1a (0.2 mmol), 2 (0.6 mmol),  $\text{Co}(\text{ClO}_4)_2 \cdot 6\text{H}_2\text{O}$  (10 mol %),  $\text{Ag}_2\text{CO}_3$  (3.0 equiv), 3-fluorobenzotrifluoride (2 mL), 170 °C, 24 h. Isolated yields.


Table 4. Scope of Thiazoles and  $\alpha$ -Oxocarboxylic Acids<sup>a</sup>

<sup>a</sup>Reaction conditions: 4 (0.2 mmol), 2 (0.6 mmol),  $\text{Co}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$  (20 mol %),  $\text{Ag}_2\text{CO}_3$  (3.0 equiv), 3-fluorobenzotrifluoride (2 mL), 170 °C, 24 h. Isolated yields.


**Schemes 1 and 2.** It was found that the addition of TEMPO resulted in the decreased yield of this reaction (**Scheme 1**, entries 1–4) and the formation of 2,2,6,6-tetramethylpiperidin-1-yl benzoate **6** (7% isolated yield) when 3 equiv of TEMPO was added (entry 4), suggesting that a radical mechanism may be implicated in the reaction. Intermolecular competition experiments between **1e** and **1f** revealed that the rate of

reaction process was no obvious different with electron-deficient or electron-rich arene as the substrate (**Scheme 2**). To gain further insight into the reaction mechanism, especially the rate-determining step for the transformation, deuterium-labeling experiments were carried out (**Schemes S1 and S2 in the Supporting Information**). Significant primary kinetic isotope effects were observed in a parallel experiment (**Scheme**

Scheme 1. Radical Trapping Experiments



Scheme 2. Intermolecular Competition Experiment



S1). Meanwhile, the intermolecular H/D exchange between D-benzoxazole [D]-1a and 2-oxo-2-phenylacetic acid 2a was also observed (Scheme S2). These results suggest that the C–H bond cleavage of benzoxazoles is rate-limiting in the process. In addition, cobalt(III) compounds were found to be able to catalyze the reaction under the oxidative reaction conditions (entries 13 and 14, Table 1), which illustrates that Co(III) species may be involved in the C–H bond cleavage step.

Although the mechanism of the reaction remains unclear, the following Co(III/IV/II) catalytic cycle (Scheme 3) has been

cycle. However, a catalytic cycle involving Co(II/III/I) oxidation states cannot be excluded at the present stage.<sup>4,5,13</sup>

In summary, we have developed an efficient cobalt(II)-catalyzed direct decarboxylative 2-benzoylation of oxazole and thiazole derivatives through an  $sp^2$  C–H bond functionalization process. This transformation is the first example of a decarboxylative C–H functionalization reaction with cobalt catalysis and provides an efficient complementary approach to important bioactive heteroaryl ketone derivatives.


## EXPERIMENTAL SECTION

**General.** All the solvents and commercially available reagents were purchased from commercial sources and used directly. Thin-layer chromatography (TLC) was performed on plates (silica gel) and visualized by fluorescence quenching under UV light. Column chromatography was performed on silica gel (200–300 Mesh) using a forced flow of 0.5–1.0 bar. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were obtained on 400 and 100 MHz spectrometers.  $^1\text{H}$  NMR data were reported as chemical shift ( $\delta$  ppm), multiplicity, coupling constant (Hz), and integration.  $^{13}\text{C}$  NMR data were reported in terms of chemical shift ( $\delta$  ppm), multiplicity, and coupling constant (Hz). Mass (HRMS) analysis was obtained using a TOF LC/MS system with electrospray ionization (ESI).

**Materials.** Azoles 1a, 1b, 1e, 1f, and 1j,  $\alpha$ -oxocarboxylic acids (2a), and thiazoles (4) were purchased from commercial sources and used directly. Azoles 1c, 1d, and 1g were prepared from condensation of the corresponding 2-aminophenol and triethyl orthoformate according to the reported procedure.<sup>14</sup> Azoles 1h and 1i were prepared from *p*-toluenesulfonylmethylisocyanide and the corresponding benzaldehyde in methanol according to the reported procedure.<sup>15</sup> Azole 1k was prepared from methyl 2-isocyanoacetate and the corresponding anhydride in THF according to the reported procedure.<sup>16</sup> Other  $\alpha$ -oxocarboxylic acids were prepared from oxidation of the corresponding methyl ketones with  $\text{SeO}_2$  according to the reported procedure.<sup>17</sup>

**General Procedures for the Synthesis of Product 3.** A 35 mL oven-dried pressure tube was charged with oxazoles 1 (0.2 mmol),  $\alpha$ -oxocarboxylic acid 2 (0.6 mmol),  $\text{Co}(\text{ClO}_4)_2 \cdot 6\text{H}_2\text{O}$  (7.3 mg, 0.02 mmol),  $\text{Ag}_2\text{CO}_3$  (165.4 mg, 0.6 mmol), and 3-F-PhCF<sub>3</sub> (2.0 mL). The

Scheme 3. A Possible Catalytic Cycle



proposed on the basis of the results above and previous reports.<sup>5b</sup>  $\text{Ag}_2\text{CO}_3$  may oxidize the  $\text{Co}^{II}$  catalyst to the  $\text{Co}^{III}$  species, which reacts with oxazole (1) in the presence of  $\text{Ag}_2\text{CO}_3$  to give the  $\text{Co}^{III}$  intermediate A. Subsequent addition of the acyl radical species B, which could be formed by the oxidation of  $\alpha$ -oxocarboxylic acid (2) in the presence of  $\text{Ag}_2\text{CO}_3$ ,<sup>13</sup> may produce cobalt(IV) species C. Reductive elimination of the species C leads to the desired product 3 and regenerating the  $\text{Co}^{II}$  catalyst, thus completing the catalytic

tube was then sealed and stirred vigorously at 170 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with DCM (20 mL) and filtered through a pad of Celite, and the filtrate was then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (1% ethyl acetate in petroleum ether, v/v) to yield the desired products 3.

**Benzodioxazol-2-yl(phenyl)methanone (3a).** White solid, 41.0 mg, yield: 92% (known compound<sup>12n,18</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58 (d, J = 8.0 Hz, 2H), 7.99 (d, J = 8.0 Hz, 1H), 7.77–7.71 (m, 2H), 7.63–7.58 (m, 3H), 7.52 (t, J = 7.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.7, 157.1, 150.4, 140.8, 135.0, 134.4, 131.03, 128.7, 128.5, 125.8, 122.4, 111.9.

**(6-Methylbenzodioxazol-2-yl)(phenyl)methanone (3b).** White solid, 29.4 mg, yield: 62% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, J = 8.0 Hz, 2H), 7.84 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 7.2 Hz, 1H), 7.60 (t, J = 7.6 Hz, 2H), 7.53 (s, 1H), 7.32 (d, J = 8.4 Hz, 1H), 2.58 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.6, 156.8, 150.8, 139.6, 138.7, 135.1, 134.2, 131.0, 128.6, 127.4, 121.8, 111.8, 22.2.

**(6-Chlorobenzodioxazol-2-yl)(phenyl)methanone (3c).** White solid, 44.3 mg, yield: 86% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.8 Hz, 1H), 7.76–7.71 (m, 2H), 7.61 (t, J = 7.6 Hz, 2H), 7.50 (d, J = 8.8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.2, 157.5, 150.6, 139.5, 134.8, 134.6, 134.4, 131.0, 128.7, 126.8, 123.0, 112.4.

**(6-Bromobenzodioxazol-2-yl)(phenyl)methanone (3d).** White solid, 49.0 mg, yield: 81% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.57–8.55 (m, 2H), 7.92 (d, J = 1.6 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.75–7.71 (m, 1H), 7.65–7.58 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.1, 157.3, 150.8, 139.9, 134.8, 134.5, 131.0, 129.5, 128.7, 123.4, 121.9, 115.3.

**(5-Methylbenzodioxazol-2-yl)(phenyl)methanone (3e).** White solid, 25.0 mg, yield: 53% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, J = 8.0 Hz, 2H), 7.75–7.70 (m, 2H), 7.60 (t, J = 7.6 Hz, 3H), 7.39 (d, J = 8.4 Hz, 1H), 2.55 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.7, 157.3, 148.7, 141.0, 135.8, 135.1, 134.2, 131.0, 129.9, 128.6, 121.9, 111.2, 21.6.

**(5-Chlorobenzodioxazol-2-yl)(phenyl)methanone (3f).** White solid, 44.8 mg, yield: 87% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.57–8.55 (m, 2H), 7.96 (d, J = 2.0 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 7.55 (dd, J = 8.8, 2.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.2, 158.1, 149.0, 141.7, 134.7, 134.6, 131.3, 131.0, 128.9, 128.7, 122.1, 112.7.

**(5-Bromobenzodioxazol-2-yl)(phenyl)methanone (3g).** White solid, 55.0 mg, yield: 91% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, J = 7.6 Hz, 2H), 8.13 (s, 1H), 7.76–7.68 (m, 2H), 7.65–7.59 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.2, 157.8, 149.4, 142.2, 134.7, 134.6, 131.6, 131.0, 128.7, 125.2, 118.5, 113.2.

**(5-(4-Methoxyphenyl)oxazol-2-yl)(phenyl)methanone (3h).** White solid, 44.6 mg, yield: 80% (known compound<sup>18</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50–8.47 (m, 2H), 7.81–7.79 (m, 2H), 7.66 (d, J = 7.2 Hz, 1H), 7.58–7.53 (m, 3H), 7.02 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.6, 161.0, 156.6, 154.4, 135.5, 133.7, 130.7, 128.4, 127.1, 122.6, 119.4, 114.6, 55.6.

**(5-(4-Bromophenyl)oxazol-2-yl)(phenyl)methanone (3i).** White solid, 53.8 mg, yield: 82% (known compound<sup>19</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.49 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.71–7.64 (m, 4H), 7.57 (t, J = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.7, 157.1, 153.2, 135.2, 133.9, 132.4, 130.8, 128.5, 126.8, 125.6, 124.3, 124.3.

**Ethyl 2-Benzoyloxazole-5-carboxylate (3j).** White solid, 30.0 mg, yield: 62% (known compound<sup>19</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.48–8.45 (m, 2H), 7.99 (s, 1H), 7.72–7.68 (m, 1H), 7.59–7.55 (m, 2H), 4.48 (q, J = 7.2 Hz, 2H), 1.45 (t, J = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.6, 158.2, 157.2, 144.1, 134.5, 134.5, 134.4, 130.9, 128.7, 62.3, 14.2.

**Methyl 2-Benzoyl-5-phenyloxazole-4-carboxylate (3k).** Yellow solid, 34.4 mg, yield: 56% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400

MHz, CDCl<sub>3</sub>) δ 8.52 (d, J = 7.6 Hz, 2H), 8.24 (d, J = 3.6 Hz, 2H), 7.70 (t, J = 7.2 Hz, 1H), 7.61–7.55 (m, 5H), 4.02 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.6, 162.1, 157.5, 154.8, 134.7, 134.3, 131.5, 131.0, 129.1, 128.7, 128.6, 128.0, 125.9, 52.7.

**Benzodioxazol-2-yl(p-tolyl)methanone (3l).** White solid, 29.4 mg, yield: 62% (known compound<sup>12n</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.49 (d, J = 8.4 Hz, 2H), 7.98 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.60–7.56 (m, 1H), 7.52–7.48 (m, 1H), 7.40 (d, J = 8.0 Hz, 2H), 2.50 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.2, 157.3, 150.4, 145.6, 140.8, 132.5, 131.2, 129.4, 128.3, 125.7, 122.3, 111.9, 21.9.

**Benzodioxazol-2-yl(4-methoxyphenyl)methanone (3m).** White solid, 31.9 mg, yield: 63% (known compound<sup>12n</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.64 (d, J = 8.8 Hz, 2H), 7.97 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.59–7.55 (m, 1H), 7.51–7.48 (m, 1H), 7.07 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.8, 164.7, 157.4, 150.3, 140.8, 133.6, 128.2, 128.0, 125.6, 122.2, 114.0, 111.8, 55.6.

**Benzodioxazol-2-yl(4-fluorophenyl)methanone (3n).** White solid, 37.0 mg, yield: 77% (known compound<sup>12n</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.72–8.67 (m, 2H), 7.98 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.62–7.50 (m, 2H), 7.31–7.25 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.8, 166.6 (d, J = 256.0 Hz), 156.9, 150.4, 140.7, 134.0 (d, J = 9.6 Hz), 131.4 (d, J = 2.9 Hz), 128.6, 125.8, 122.4, 115.9 (d, J = 21.9 Hz), 111.9.

**Benzodioxazol-2-yl(4-chlorophenyl)methanone (3o).** White solid, 37.0 mg, yield: 72% (known compound<sup>19</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60–8.56 (m, 2H), 7.97 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.61–7.55 (m, 3H), 7.53–7.49 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.1, 156.8, 150.4, 141.1, 140.7, 133.3, 132.5, 129.0, 128.7, 125.9, 122.4, 111.9.

**Benzodioxazol-2-yl(4-bromophenyl)methanone (3p).** White solid, 40.5 mg, yield: 67% (known compound<sup>12n</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.51–8.49 (m, 2H), 7.97 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 3H), 7.61–7.57 (m, 1H), 7.51 (t, J = 7.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.4, 156.8, 150.4, 140.7, 133.7, 132.5, 132.0, 130.0, 128.7, 125.9, 122.5, 111.9.

**Benzodioxazol-2-yl(3-fluorophenyl)methanone (3q).** White solid, 39.0 mg, yield: 81% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.45–8.42 (m, 1H), 8.36–8.32 (m, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.63–7.56 (m, 2H), 7.54–7.50 (m, 1H), 7.45–7.40 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.1 (d, J = 2.0 Hz), 162.6 (d, J = 246.0 Hz), 156.8, 150.5, 140.7, 136.8 (d, J = 7.1 Hz), 130.3 (d, J = 7.7 Hz), 128.7, 126.9 (d, J = 3.1 Hz), 125.9, 122.5, 121.4 (d, J = 21.4 Hz), 117.8 (d, J = 23.5 Hz), 111.9.

**Benzodioxazol-2-yl(3-chlorophenyl)methanone (3r).** White solid, 46.2 mg, yield: 90% (known compound<sup>19</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59 (t, J = 2.0 Hz, 1H), 8.54–8.51 (m, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.70–7.67 (m, 1H), 7.63–7.57 (m, 1H), 7.55–7.50 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.1, 156.7, 150.5, 140.7, 136.4, 134.9, 134.2, 130.9, 123.0, 129.2, 128.8, 125.9, 122.6, 111.9.

**Benzodioxazol-2-yl(3-bromophenyl)methanone (3s).** White solid, 40.0 mg, yield: 80% (known compound<sup>18</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.73 (t, J = 2.0 Hz, 1H), 8.59–8.57 (m, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.85–7.82 (m, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.62–7.58 (m, 1H), 7.54–7.46 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.0, 156.6, 150.5, 140.7, 137.1, 136.6, 133.8, 130.2, 129.7, 128.8, 125.9, 122.8, 122.6, 111.9.

**Benzodioxazol-2-yl(3-(trifluoromethyl)phenyl)methanone (3t).** White solid, 44.2 mg, yield: 76% (known compound<sup>10a</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.89–8.84 (m, 2H), 8.01–7.96 (m, 2H), 7.77–7.74 (m, 2H), 7.64–7.60 (m, 1H), 7.55–7.51 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 179.1, 156.6, 150.5, 140.7, 135.5, 134.3, 131.4 (q, J = 33.0 Hz), 130.6 (q, J = 3.5 Hz), 129.3, 128.9, 127.9 (q, J = 3.9 Hz), 126.0, 122.6, 123.7 (q, J = 274.0 Hz), 112.0.

**General Procedures for the Synthesis of Product 5.** A 35 mL oven-dried pressure tube was charged with thiazoles 4 (0.2 mmol),  $\alpha$ -oxocarboxylic acid 2 (0.6 mmol), Co(OAc)<sub>2</sub>·4H<sub>2</sub>O (7.6 mg, 0.04 mmol), Ag<sub>2</sub>CO<sub>3</sub> (165.4 mg, 0.6 mmol), and 3-F-PhCF<sub>3</sub> (2.0 mL). The

tube was then sealed and stirred vigorously at 170 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with DCM (20 mL) and filtered through a pad of Celite, and the filtrate was then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (gradient eluent of 1% ethyl acetate in petroleum ether, v/v) to yield the desired products **5**.

**Benzod[d]thiazol-2-yl(phenyl)methanone (5a).** Yellow solid, 28.7 mg, yield: 60% (known compound<sup>19</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59–8.57 (m, 2H), 8.29–8.27 (m, 1H), 8.07–8.04 (m, 1H), 7.72–7.69 (m, 1H), 7.64–7.56 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 185.4, 167.1, 153.9, 137.0, 135.0, 134.0, 131.3, 128.6, 127.7, 127.0, 125.8, 122.2.

**Benzod[d]thiazol-2-yl(p-tolyl)methanone (5b).** Yellow solid, m.p.: 89–90 °C, 21.8 mg, yield: 43%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50 (d, J = 7.6 Hz, 2H), 8.27 (d, J = 8.0 Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 7.62–7.57 (m, 2H), 7.39 (d, J = 7.2 Hz, 2H), 2.50 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 185.0, 167.5, 153.9, 145.0, 137.0, 132.4, 131.4, 129.3, 127.5, 126.9, 125.7, 122.2, 21.9. IR (neat) ν 3004, 2916, 1637, 1566, 1318, 1273, 1183, 1116, 889, 833, 764, 705 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>15</sub>H<sub>12</sub>NOS (M + H)<sup>+</sup>: 254.0634, found: 254.0628.

**Benzod[d]thiazol-2-yl(4-chlorophenyl)methanone (5c).** Yellow solid, m.p.: 91–92 °C, 27.4 mg, yield: 50%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60–8.57 (m, 2H), 8.28–8.26 (m, 1H), 8.06–8.04 (m, 1H), 7.65–7.56 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.1, 166.8, 153.8, 140.6, 137.1, 133.3, 132.7, 128.9, 127.8, 127.1, 125.8, 122.2. IR (neat) ν 3005, 2316, 1638, 1585, 1320, 1275, 1175, 1117, 891, 835, 764, 708 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>14</sub>H<sub>9</sub>ClNOS (M + H)<sup>+</sup>: 274.0088, found: 274.0077.

**Benzod[d]thiazol-2-yl(4-bromophenyl)methanone (5d).** Yellow solid, m.p.: 90–91 °C, 26.0 mg, yield: 41%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.49 (d, J = 8.4 Hz, 2H), 8.27 (d, J = 8.0 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.65–7.57 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.3, 166.8, 153.8, 137.1, 133.7, 132.8, 131.9, 129.5, 127.8, 127.1, 125.8, 122.2. IR (neat) ν 3010, 2987, 1639, 1581, 1394, 1275, 1173, 1115, 891, 835, 749, 710 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>14</sub>H<sub>9</sub>BrNOS (M + H)<sup>+</sup>: 317.9583, found: 317.9568.

**Benzod[d]thiazol-2-yl(4-(trifluoromethyl)phenyl)methanone (5e).** Yellow solid, m.p.: 95–96 °C, 42.3 mg, yield: 69%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.69 (d, J = 8.0 Hz, 2H), 8.28 (d, J = 7.6 Hz, 1H), 8.07 (d, J = 7.6 Hz, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.66–7.59 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.6, 166.3, 153.8, 137.8, 137.1, 134.9 (q, J = 32.7 Hz), 131.6, 128.1, 127.2, 125.9, 125.56 (q, J = 3.7 Hz), 126.3 (q, J = 272.0 Hz), 122.3. IR (neat) ν 3061, 3004, 1655, 1486, 1320, 1275, 1170, 1154, 893, 852, 715, 706 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>15</sub>H<sub>9</sub>F<sub>3</sub>NOS (M + H)<sup>+</sup>: 308.0351, found: 308.0337.

**(5-Chlorobenzod[d]thiazol-2-yl)(4-(trifluoromethyl)phenyl)methanone (5f).** Yellow solid, m.p.: 135–136 °C, 38.4 mg, yield: 57%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (d, J = 8.0 Hz, 2H), 8.13 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 2.4 Hz, 1H), 7.23 (dd, J = 9.2, 2.4 Hz, 1H), 3.96 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.3, 163.7, 160.1, 148.5, 139.3, 138.1, 134.8 (q, J = 32.2 Hz), 131.4, 126.6, 125.4 (q, J = 3.7 Hz), 123.7 (q, J = 274.2 Hz), 118.0, 103.4, 55.9. IR (neat) ν 3005, 2989, 1646, 1538, 1327, 1275, 1169, 1118, 897, 858, 763, 705 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>16</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>2</sub>S (M + H)<sup>+</sup>: 338.0457, found: 338.0443.

**(6-Bromobenzod[d]thiazol-2-yl)(4-(trifluoromethyl)phenyl)methanone (5g).** Yellow solid, m.p.: 104–105 °C, 41.0 mg, yield: 60%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.68 (d, J = 8.0 Hz, 2H), 8.27 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.58 (dd, J = 8.4, 2.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.1, 168.0, 154.5, 137.5, 135.3, 135.1 (q, J = 32.8 Hz), 133.3, 131.6, 128.7, 125.5 (q, J = 3.7 Hz), 125.4, 123.1, 123.6 (q, J = 271.0 Hz). IR (neat) ν = 3005, 2989, 1650, 1583, 1325, 1275, 1170, 1129, 892, 839, 765, 704 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>15</sub>H<sub>8</sub>ClF<sub>3</sub>NOS (M + H)<sup>+</sup>: 341.9962, found: 341.9948.

**(6-Methoxybenzod[d]thiazol-2-yl)(4-(trifluoromethyl)phenyl)methanone (5h).** Yellow solid, m.p.: 97–99 °C, 54.8 mg, yield: 71%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.68 (d, J = 8.0 Hz, 2H), 8.21 (s, 1H), 8.12 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.0 Hz, 2H), 7.73 (dd, J = 8.8, 1.2 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.1, 166.7, 152.6, 138.6,

137.5, 135.0 (q, J = 32.7 Hz), 131.5, 131.0, 126.9, 125.5 (q, J = 3.7 Hz), 123.6 (q, J = 272.3 Hz), 124.9, 122.5. IR (neat) ν 3005, 2989, 1643, 1495, 1325, 1275, 1174, 1110, 865, 830, 765, 704 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>15</sub>H<sub>8</sub>BrF<sub>3</sub>NOS (M + H)<sup>+</sup>: 385.9457, found: 385.9440.

**(4,5-Dimethylthiazol-2-yl)(4-(trifluoromethyl)phenyl)methanone (5i).** Yellow oil, 33.6 mg, yield: 59%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.55 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 2.51 (s, 3H), 2.48 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 182.9, 161.7, 152.2, 138.4, 136.9, 134.3 (q, J = 32.7 Hz), 131.3, 125.2 (q, J = 3.7 Hz), 123.7 (q, J = 271.0 Hz), 15.1, 12.0. IR (neat) ν 3002, 2913, 1623, 1564, 1324, 1260, 1171, 1115, 918, 806, 750, 702 cm<sup>-1</sup>. HRMS (ESI, m/z): calcd. for C<sub>13</sub>H<sub>10</sub>F<sub>3</sub>NOS (M + H)<sup>+</sup>: 286.0508, found: 286.0513.

**2,2,6,6-Tetramethylpiperidin-1-yl Benzoate (6).** White soild, 10.9 mg, yield: 7% (3 equiv TEMPO for 1 h). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16–8.04 (m, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 1.89–1.44 (m, 6H), 1.30 (s, 6H), 1.15 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 166.4, 132.8, 129.8, 129.6, 128.5, 60.4, 39.1, 32.0, 20.9, 17.0. HRMS (ESI, m/z): calcd. for C<sub>16</sub>H<sub>24</sub>NO<sub>2</sub> (M + H)<sup>+</sup>: 262.1802, found: 262.1788.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.joc.5b01450](https://doi.org/10.1021/acs.joc.5b01450).

<sup>1</sup>H and <sup>13</sup>C NMR spectra of the desired product. Deuterium labeling studies ([PDF](#))

## AUTHOR INFORMATION

### Corresponding Authors

\*E-mail: haosun@nju.edu.cn (H.S.).

\*E-mail: guigenli@nju.edu.cn (G.L.).

\*E-mail: hongjianlu@nju.edu.cn (H.L.).

### Author Contributions

§(K.Y., X.C.) These individuals contributed equally to this research.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We gratefully acknowledge the financial support from the National Natural Science Foundation of China (21332005, 21372115, 21472085), the Ph.D. Programs Foundation of the Ministry of Education of China (Grant 20130091120046), the Natural Science Foundation of Jiangsu Province (BK2012012, BK20131267), the Qing Lan Project, and the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RGP VPP-207.

## REFERENCES

- (1) For selected recent reviews, see: (a) Su, B.; Cao, Z.; Shi, Z. *Acc. Chem. Res.* **2015**, *48*, 886–896. (b) Ackermann, L. *Acc. Chem. Res.* **2014**, *47*, 281–295. (c) Corbet, M.; De Campo, F. *Angew. Chem., Int. Ed.* **2013**, *52*, 9896–9898. (d) Rouquet, G.; Chatani, N. *Angew. Chem., Int. Ed.* **2013**, *52*, 11726–11743. (e) Engle, K. M.; Mei, T.; Wasa, M.; Yu, J. *Acc. Chem. Res.* **2012**, *45*, 788–802. (f) White, M. C. *Science* **2012**, *335*, 807–809. (g) Colby, D. A.; Tsai, A. S.; Bergman, R. G.; Ellman, J. A. *Acc. Chem. Res.* **2012**, *45*, 814–825. (h) Sun, C.; Li, B.; Shi, Z. *Chem. Rev.* **2011**, *111*, 1293–1314. (i) McMurray, L.; O'Hara, F.; Gaunt, M. J. *Chem. Soc. Rev.* **2011**, *40*, 1885–1898. (j) Gutekunst, W. R.; Baran, P. S. *Chem. Soc. Rev.* **2011**, *40*, 1976–1991. (k) Wencel-Delord, J.; Drogé, T.; Liu, F.; Glorius, F. *Chem. Soc. Rev.* **2011**, *40*, 4740–4761. (l) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068–5083. (m) Yeung, C. S.; Dong, V. *Chem. Rev.* **2011**, *111*, 1215–1292. (n) Hopkinson, M. N.; Gee, A. D.;

Gouverneur, V. *Chem. - Eur. J.* **2011**, *17*, 8248–8262. (o) Xu, L.; Li, B.; Yang, Z.; Shi, Z. *Chem. Soc. Rev.* **2010**, *39*, 712–733. (p) Knappke, C. E. I.; von Wangelin, A. *J. Angew. Chem., Int. Ed.* **2010**, *49*, 3568–3570. (q) Lyons, T. W.; Sanford, M. S. *Chem. Rev.* **2010**, *110*, 1147–1169. (r) Ackermann, L. *Chem. Commun.* **2010**, *46*, 4866–4877. (s) Colby, D. A.; Bergman, R. G.; Ellman, J. A. *Chem. Rev.* **2010**, *110*, 624–655. (2) (a) Cai, X.; Xie, B. *Curr. Org. Chem.* **2015**, *19*, 121–150. (b) Hyster, T. K. *Catal. Lett.* **2015**, *145*, 458–467. (c) Tilly, D.; Dayaker, G.; Bachu, P. *Catal. Sci. Technol.* **2014**, *4*, 2756–2777. (d) Yoshikai, N. *Yuki Gosei Kagaku Kyokaishi* **2014**, *72*, 1198–1206. (e) Yoshikai, N. *Bull. Chem. Soc. Jpn.* **2014**, *87*, 843–857. (f) Gao, K.; Yoshikai, N. *Acc. Chem. Res.* **2014**, *47*, 1208–1219. (g) Ackermann, L. *J. Org. Chem.* **2014**, *79*, 8948–8954. (h) Yoshikai, N. *Synlett* **2011**, *2011*, 1047–1051. (i) Kulkarni, A. A.; Daugulis, O. *Synthesis* **2009**, 4087–4109.

(3) For selected reviews, see: (a) Pellissier, H.; Clavier, H. *Chem. Rev.* **2014**, *114*, 2775–2823. (b) Jahn, U. In *Radicals in Synthesis III*; Gansäuer, A., Heinrich, M., Eds.; Springer: Heidelberg, 2012; Vol. 320, pp 191–322. (c) Lu, H.; Zhang, X. P. *Chem. Soc. Rev.* **2011**, *40*, 1899–1909. (d) Intrieri, D.; Caselli, A.; Gallo, E. *Eur. J. Inorg. Chem.* **2011**, *2011*, 5071–5074. (e) Cahiez, G.; Moyeux, A. *Chem. Rev.* **2010**, *110*, 1435–1462. (f) Hess, W.; Treutwein, J.; Hilt, G. *Synthesis* **2008**, 3008, 3537–3562.

(4) For selected recent examples, see: (a) Zhao, D.; Kim, J. H.; Stegemann, L.; Strassert, C. A.; Glorius, F. *Angew. Chem., Int. Ed.* **2015**, *54*, 4508–4511. (b) Hummel, J. R.; Ellman, J. A. *J. Am. Chem. Soc.* **2015**, *137*, 490–498. (c) Fallon, B. J.; Derat, E.; Amatore, M.; Aubert, C.; Chemla, F.; Ferreira, F.; Perez-Luna, A.; Petit, M. *J. Am. Chem. Soc.* **2015**, *137*, 2448–2451. (d) Wu, C.; Zhong, J.; Meng, Q.; Lei, T.; Gao, X.; Tung, C.; Wu, L. *Org. Lett.* **2015**, *17*, 884–887. (e) Pawar, A. B.; Chang, S. *Org. Lett.* **2015**, *17*, 660–663. (f) Li, J.; Ackermann, L. *Chem. - Eur. J.* **2015**, *21*, 5718–5722. (g) Li, J.; Ackermann, L. *Angew. Chem., Int. Ed.* **2015**, *54*, 3635–3638. (h) Ma, W.; Ackermann, L. *ACS Catal.* **2015**, *5*, 2822–2825. (i) Lee, P.-S.; Yoshikai, N. *Org. Lett.* **2015**, *17*, 22–25. (j) Grigorjeva, L.; Daugulis, O. *Org. Lett.* **2014**, *16*, 4688–4690. (k) Grigorjeva, L.; Daugulis, O. *Org. Lett.* **2014**, *16*, 4684–4687. (l) Gao, K.; Paira, R.; Yoshikai, N. *Adv. Synth. Catal.* **2014**, *356*, 1486–1490. (m) Grigorjeva, L.; Daugulis, O. *Angew. Chem., Int. Ed.* **2014**, *53*, 10209–10212. (n) Yu, D.; Gensch, T.; de Azambuja, F.; Vasquez-Cespedes, S.; Glorius, F. *J. Am. Chem. Soc.* **2014**, *136*, 17722–17725. (o) Ikemoto, H.; Yoshino, T.; Sakata, K.; Matsunaga, S.; Kanai, M. *J. Am. Chem. Soc.* **2014**, *136*, 5424–5431. (p) Gao, K.; Yoshikai, N. *J. Am. Chem. Soc.* **2013**, *135*, 9279–9282. (q) Yoshino, T.; Ikemoto, H.; Matsunaga, S.; Kanai, M. A. *Angew. Chem., Int. Ed.* **2013**, *52*, 2207–2211. (r) Yao, T.; Hirano, K.; Satoh, T.; Miura, M. *Angew. Chem., Int. Ed.* **2012**, *51*, 775–779. (s) Song, W.; Ackermann, L. *Angew. Chem., Int. Ed.* **2012**, *51*, 8251–8254. (t) Chen, Q.; Ilies, L.; Nakamura, E.-I. *J. Am. Chem. Soc.* **2011**, *133*, 428–429. (u) Li, B.; Wu, Z.; Gu, Y.; Sun, C.; Wang, B.; Shi, Z. *Angew. Chem., Int. Ed.* **2011**, *50*, 1109–1113. (v) Gao, K.; Lee, P. S.; Fujita, T.; Yoshikai, N. *J. Am. Chem. Soc.* **2010**, *132*, 12249–12251. (w) Ding, Z.; Yoshikai, N. *Org. Lett.* **2010**, *12*, 4180–4183. For the first example of cobalt-catalyzed C–H functionalization, see: (x) Murahashi, S. *J. Am. Chem. Soc.* **1955**, *77*, 6403–6404.

(5) Selected examples of C–O bond formation; see: (a) Zhang, L.; Hao, X.; Zhang, S.; Liu, Z.; Zheng, X.; Gong, J.; Niu, J.; Song, M. *Angew. Chem., Int. Ed.* **2015**, *54*, 272–275. Selected examples of C–N bond formations; see: (b) Wu, X.; Yang, K.; Zhao, Y.; Sun, H.; Li, G.; Ge, H. *Nat. Commun.* **2015**, *6*, 6462. (c) Sun, B.; Yoshino, T.; Matsunaga, S.; Kanai, M. *Chem. Commun.* **2015**, *51*, 4659–4661. (d) Patel, P.; Chang, S. *ACS Catal.* **2015**, *5*, 853–858. (e) Lu, H.; Li, C.; Jiang, H.; Lizardi, C.; Zhang, X. P. *Angew. Chem., Int. Ed.* **2014**, *53*, 7028–7032. (f) Jin, L.; Lu, H.; Cui, Y.; Lizardi, C. L.; Arzua, T. N.; Wojtas, L.; Cui, X.; Zhang, X. P. *Chem. Sci.* **2014**, *5*, 2422–2427. (g) Zardi, P.; Intrieri, D.; Caselli, A.; Gallo, E. *J. Organomet. Chem.* **2012**, *716*, 269–274. (h) Kim, J.; Cho, S.; Joseph, J.; Chang, S. *Angew. Chem., Int. Ed.* **2010**, *49*, 9899–9903. (i) Lu, H.; Jiang, H.; Wojtas, L.; Zhang, X. P. *Angew. Chem., Int. Ed.* **2010**, *49*, 10192–10196. (j) Cenini,

S.; Gallo, E.; Penoni, A.; Ragaini, F.; Tollari, S. *Chem. Commun.* **2000**, 2265–2267.

(6) For selected recent reviews, see: (a) Miao, J.; Ge, H. *Synlett* **2014**, *25*, 911–919. (b) Cornell, J.; Larrosa, I. *Synthesis* **2012**, *44*, 653–676. (c) Rodriguez, N.; Goossen, L. *J. Chem. Soc. Rev.* **2011**, *40*, 5030–5048. (d) Shang, R.; Liu, L. *Sci. China: Chem.* **2011**, *54*, 1670–1687. (e) Bonesi, S. M.; Fagnoni, M. *Chem. - Eur. J.* **2010**, *16*, 13572–13589. (f) Goossen, L. J.; Rodriguez, N.; Goossen, K. *Angew. Chem., Int. Ed.* **2008**, *47*, 3100–3120. (g) Baudoin, O. *Angew. Chem., Int. Ed.* **2007**, *46*, 1373–1375.

(7) For selected examples of Pd-catalyzed decarboxylative C–H functionalization reactions, see: (a) Pei, K.; Jie, X.; Zhao, H.; Su, W. *Eur. J. Org. Chem.* **2014**, *2014*, 4230–4233. (b) Luo, L.; Wu, D.; Li, W.; Zhang, S.; Ma, Y.; Yan, S.; You, J. *Org. Lett.* **2014**, *16*, 6080–6083. (c) Maetani, S.; Fukuyama, T.; Ryu, I. *Org. Lett.* **2013**, *15*, 2754–2757. (d) Hu, P.; Zhang, M.; Jie, X.; Su, W. *Angew. Chem., Int. Ed.* **2012**, *51*, 227–231. (e) Zhao, H.; Wei, Y.; Xu, J.; Kan, J.; Su, W.; Hong, M. *J. Org. Chem.* **2011**, *76*, 882–893. (f) Zhang, F.; Greaney, M. F. *Angew. Chem., Int. Ed.* **2010**, *49*, 2768–2771. (g) Zhou, J.; Hu, P.; Zhang; Huang, M.; Wang, M.; Su, W. *Chem. - Eur. J.* **2010**, *16*, 5876–5881. (h) Xie, K.; Yang, Z.; Zhou, X.; Li, X.; Wang, S.; Tan, Z.; An, X.; Guo, C. *Org. Lett.* **2010**, *12*, 1564–1567. (i) Wang, C.; Rakshit, S.; Glorius, F. *J. Am. Chem. Soc.* **2010**, *132*, 14006–14008. (j) Cornell, J.; Lu, P.; Larrosa, I. *Org. Lett.* **2009**, *11*, 5506. (k) Wang, C.; Piel, I.; Glorius, F. *J. Am. Chem. Soc.* **2009**, *131*, 4194–4195. (l) Yu, W.; Sit, W. N.; Zhou, Z.; Chan, A. S. C. *Org. Lett.* **2009**, *11*, 3174–3177. For the first example, see: (m) Voutchkova, A.; Coplin, A.; Leadbeater, N. E.; Crabtree, R. H. *Chem. Commun.* **2008**, 6312–6314.

(8) For recent examples of Pd-catalyzed decarboxylative C–H functionalization reactions with a directing group: (a) Liu, X.; Yi, Z.; Wang, J.; Liu, G. *RSC Adv.* **2015**, *5*, 10641–10646. (b) Yao, J.; Feng, R.; Wu, Z.; Liu, Z.; Zhang, Y. *Adv. Synth. Catal.* **2013**, *355*, 1517–1522. (c) Li, H.; Li, P.; Tan, H.; Wang, L. *Chem. - Eur. J.* **2013**, *19*, 14432–14436. (d) Kim, M.; Park, Sharma, S.; Kim, A.; Park, E.; Kwak, J. H.; Jung, Y. H.; Kim, I. S. *Chem. Commun.* **2013**, *49*, 925–927. (e) Yang, Z.; Chen, X.; Liu, J.; Gui, Q.; Xie, K.; Li, M.; Tan, Z. *Chem. Commun.* **2013**, *49*, 1560–1562. (f) Park, J.; Kim, M.; Sharma, S.; Park, E.; Kim, A.; Lee, S. H.; Kwak, J. H.; Jung, Y. H.; Kim, I. S. *Chem. Commun.* **2013**, *49*, 1654–1656. (g) Sharma, S.; Kim, A.; Park, E.; Park, J.; Kim, M.; Kwak, J. H.; Lee, S. H.; Jung, Y. H.; Kim, I. S. *Adv. Synth. Catal.* **2013**, *355*, 667–672. (h) Pan, C.; Jin, H.; Liu, X.; Cheng, Y.; Zhu, C. *Chem. Commun.* **2013**, *49*, 2933–2935. (i) Li, Z.; Li, D.; Wang, G. *J. Org. Chem.* **2013**, *78*, 10414–10420. (j) Cai, H.; Li, D.; Liu, Z.; Wang, G. *Huaxue Xuebao* **2013**, *71*, 717–721. (k) Yao, J.; Feng, R.; Wu, Z.; Liu, Z.; Zhang, Y. *Adv. Synth. Catal.* **2013**, *355*, 1517–1522. (l) Li, H.; Li, P.; Zhao, Q.; Wang, L. *Chem. Commun.* **2013**, *49*, 9170–9172. (m) Sharma, S.; Khan, I. A.; Saxena, A. K. *Adv. Synth. Catal.* **2013**, *355*, 673–678. (n) Wang, H.; Guo, L.; Duan, X. *Org. Lett.* **2012**, *14*, 4358–4361.

(9) For recent examples of Pd-catalyzed decarboxylative C–H acylation reactions, see: (a) Gong, W.; Liu, D.; Li, F.; Gao, J.; Li, H.; Lang, J. *Tetrahedron* **2015**, *71*, 1269–1275. (b) Miao, J.; Ge, H. *Org. Lett.* **2013**, *15*, 2930–2933. (c) Li, M.; Wang, C.; Ge, H. *Org. Lett.* **2011**, *13*, 2062–2064. (d) Li, M.; Ge, H. *Org. Lett.* **2010**, *12*, 3464–3467. (e) Fang, P.; Li, M.; Ge, H. *J. Am. Chem. Soc.* **2010**, *132*, 11898–11899.

(10) For selected examples of Ni catalysis, see: (a) Yang, K.; Zhang, C.; Wang, P.; Zhang, Y.; Ge, H. *Chem. - Eur. J.* **2014**, *20*, 7241–7244. (b) Yang, K.; Wang, P.; Zhang, C.; Kadi, A. A.; Fun, H. K.; Zhang, Y.; Lu, H. *Eur. J. Org. Chem.* **2014**, *2014*, 7586–7589. Ag catalysis, see: (c) Mai, W.; Sun, B.; You, L.; Yang, L.; Mao, P.; Yuan, J.; Xiao, Y.; Qu, L. *Org. Biomol. Chem.* **2015**, *13*, 2750–2755. (d) Wang, H.; Zhou, S.; Guo, L.; Duan, X. *Tetrahedron* **2015**, *71*, 630–636. (e) Zhao, W.; Chen, X.; Yuan, J.; Qu, L.; Duan, L.; Zhao, Y. *Chem. Commun.* **2014**, *50*, 2018–2120. (f) Suresh, R.; Kumaran, R. S.; Senthilkumar, V.; Muthusubramanian, S. *RSC Adv.* **2014**, *4*, 31685–31688. Rh catalysis, see: (g) Zhang, L.; Xue, X.; Xu, C.; Pan, Y.; Zhang, G.; Xu, L.; Li, H.; Shi, Z. *ChemCatChem* **2014**, *6*, 3069–3074. Cu catalysis, see: (h) Wang, C.; Wang, S.; Li, H.; Yan, J.; Chi, H.; Chen, X.; Zhang, Z.

*Org. Biomol. Chem.* **2014**, *12*, 1721–1724. (i) Li, D.; Wang, M.; Liu, J.; Zhao, Q.; Wang, L. *Chem. Commun.* **2013**, *49*, 3640–3642. (j) Yu, L.; Li, P.; Wang, L. *Chem. Commun.* **2013**, *49*, 2368–2370.

(11) For selected recent examples, see: (a) Haffner, C. D.; Becherer, J. D.; Boros, E. E.; Cadilla, R.; Carpenter, T.; Cowan, D.; Deaton, D. N.; Guo, Y.; Harrington, W.; Henke, B. R.; Jeune, M. R.; Kaldor, I.; Milliken, N.; Petrov, K. G.; Preugschat, F.; Schulte, C.; Shearer, B. G.; Shearer, T.; Smalley, T. L.; Stewart, E. L.; Stuart, J. D.; Ulrich, J. C. *J. Med. Chem.* **2015**, *58*, 3548–3571. (b) Kim, M.; Jeon, J.; Song, J.; Suh, K. H.; Kim, Y. H.; Min, K. H.; Lee, K. O. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 3140–3144. (c) Mandadapu, S. R.; Weerawarna, P. M.; Gunnam, M. R.; Alliston, K. R.; Lushington, G. H.; Kim, Y.; Chang, K.; Groutas, W. C. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 4820–4826. (d) Rusch, M.; Zahov, S.; Vetter, I. R.; Lehr, M.; Hedberg, C. *Bioorg. Med. Chem.* **2012**, *20*, 1100–1112. (e) He, T.; Li, H.; Li, P.; Wang, L. *Chem. Commun.* **2011**, *47*, 8946–8948. (f) He, T.; Yu, L.; Zhang, L.; Wang, L.; Wang, M. *Org. Lett.* **2011**, *13*, 5016–5019. (g) McKee, L. M.; Kerwin, S. M. *Bioorg. Med. Chem.* **2008**, *16*, 1775–1783. (h) Min, J.; Lee, J. W.; Ahn, Y. H.; Chang, Y. J. *Comb. Chem.* **2007**, *9*, 1079–1083. (i) Riego, E.; Hernandez, D.; Albericio, F.; Alvarez, M. *Synthesis* **2005**, *2005*, 1907–1922. (j) Yeh, V. S. C. *Tetrahedron* **2004**, *60*, 11995–12042. (k) Sato, S.; Kajiura, T.; Noguchi, M.; Takehana, K.; Kobayashi, T.; Tsuji, T. *J. J. Antibiot.* **2001**, *54*, 102–104. (l) Gong, Z.; Leu, C.; Wu, F.; Shu, C. *Macromolecules* **2000**, *33*, 8527–8533.

(12) For recent selected examples of transition-metal-catalyzed direct C-2 functionalizations of oxazoles and thiazoles, see: (a) Zhu, F.; Wang, Z.-X. *Org. Lett.* **2015**, *17*, 1601–1604. (b) Gao, F.; Kim, B.; Walsh, P. J. *Chem. Commun.* **2014**, *50*, 10661–10664. (c) Feng, Q.; Song, Q. *Adv. Synth. Catal.* **2014**, *356*, 2445–2452. (d) Nishino, M.; Hirano, K.; Satoh, T.; Miura, M. *Angew. Chem., Int. Ed.* **2013**, *52*, 4457–4461. (e) Yu, X.; Li, X.; Wan, B. *Org. Biomol. Chem.* **2012**, *10*, 7479–7482. (f) Sharma, S.; Khan, I. A.; Saxena, A. K. *Adv. Synth. Catal.* **2013**, *355*, 673–678. (g) Muto, K.; Yamaguchi, J.; Itami, K. *J. Am. Chem. Soc.* **2012**, *134*, 169–172. (h) Wu, G.; Zhou, J.; Zhang, M.; Hu, P.; Su, W. *Chem. Commun.* **2012**, *48*, 8964–8966. (i) Wang, M.; Li, D.; Zhou, W.; Wang, L. *Tetrahedron* **2012**, *68*, 1926–1930. (j) Amaike, K.; Muto, K.; Yamaguchi, J.; Itami, K. *J. Am. Chem. Soc.* **2012**, *134*, 13573–13576. (k) Li, C.; Li, P.; Yang, J.; Wang, L. *Chem. Commun.* **2012**, *48*, 4214–4216. (l) Han, W.; Mayer, P.; Ofial, A. R. *Chem. - Eur. J.* **2011**, *17*, 6904–6908. (m) Yang, F.; Xu, Z.; Wang, Z.; Yu, Z.; Wang, R. *Chem. - Eur. J.* **2011**, *17*, 6321–6325. (n) Wu, X.; Anbarasan, P.; Neumann, H.; Beller, M. *Angew. Chem., Int. Ed.* **2010**, *49*, 7316–7319. (o) Hachiya, H.; Hirano, K.; Satoh, T.; Miura, M. *Angew. Chem., Int. Ed.* **2010**, *49*, 2202–2205. (p) Ackermann, L.; Barfusser, S.; Pospech, J. *Org. Lett.* **2010**, *12*, 724–726.

(13) (a) Cheng, K.; Zhao, B.; Qi, C. *RSC Adv.* **2014**, *4*, 48698–48702. (b) Punta, F.; Minisci, C. *Trends Heterocycl. Chem.* **2008**, *13*, 1–68. (c) Fontana, F.; Minisci, F.; Barbosa, M. C. N.; Vismara, E. J. *Org. Chem.* **1991**, *56*, 2866–2869. (d) Minisci, F.; Vismara, E.; Fontana, F. *Heterocycles* **1989**, *28*, 489–519.

(14) Wertz, S.; Kodama, S.; Studer, A. *Angew. Chem., Int. Ed.* **2011**, *50*, 11511–11515.

(15) Pippel, D. J.; Mapes, C. M.; Mani, N. S. *J. Org. Chem.* **2007**, *72*, 5828–5831.

(16) Suzuki, M.; Iwasaki, T.; Miyoshi, M.; Okumura, K.; Matsumoto, K. *J. Org. Chem.* **1973**, *38*, 3571–3575.

(17) Wadhwa, K.; Yang, C.; West, P. R.; Deming, K. C.; Chemburkar, S. R.; Reddy, R. E. *Synth. Commun.* **2008**, *38*, 4434–4444.

(18) Toh, Q. Y.; McNally, A.; Vera, S.; Erdmann, N.; Gaunt, M. J. *J. Am. Chem. Soc.* **2013**, *135*, 3772–3775.

(19) Lassalas, P.; Marsais, F.; Hoarau, C. *Synlett* **2013**, *24*, 2233–2240.